Angiogenesis as a therapeutic target in malignant gliomas.

Currently, adult glioblastoma (GBM) patients have poor outcomes with conventional cytotoxic treatments. Because GBMs are highly angiogenic tumors, inhibitors that target tumor vasculature are considered promising therapeutic agents in these patients. Encouraging efficacy and tolerability in preliminary clinical trials suggest that targeting angiogenesis may be an effective therapeutic strategy in GBM patients. However, the survival benefits observed to date in uncontrolled trials of antiangiogenic agents have been modest, and several obstacles have limited their effectiveness. This article reviews the rationale for antiangiogenic agents in GBM, their potential mechanisms of action, and their clinical development in GBM patients. Although challenges remain with this approach, ongoing studies may improve upon the promising initial benefits already observed in GBM patients.

[1]  Alessia Pica,et al.  Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Chamberlain.  BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMAS: EFFICACY, TOXICITY, AND PATTERNS OF RECURRENCE , 2009, Neurology.

[3]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Wen,et al.  A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. , 2009, International journal of radiation oncology, biology, physics.

[5]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[6]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[7]  P. Wen,et al.  Response criteria for glioma , 2008, Nature Clinical Practice Oncology.

[8]  A. Friedman,et al.  Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas , 2008, Clinical Cancer Research.

[9]  P. Kelly,et al.  Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. , 2008, International journal of radiation oncology, biology, physics.

[10]  P. Kelly,et al.  High-grade glioma before and after treatment with radiation and Avastin: initial observations. , 2008, Neuro-oncology.

[11]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[12]  B. Garmy-Susini,et al.  Integrins in angiogenesis and lymphangiogenesis , 2008, Nature Reviews Cancer.

[13]  G. Neufeld,et al.  The semaphorins: versatile regulators of tumour progression and tumour angiogenesis , 2008, Nature Reviews Cancer.

[14]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[15]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[16]  T. Cloughesy,et al.  Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. , 2008, International journal of radiation oncology, biology, physics.

[17]  S. Taillibert,et al.  [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. , 2008, Revue neurologique.

[18]  H. Friedman,et al.  Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas , 2008 .

[19]  Susan M. Chang,et al.  Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 , 2008 .

[20]  H. Friedman,et al.  Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG) , 2008 .

[21]  P. Wen,et al.  Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen , 2008 .

[22]  T. Mikkelsen,et al.  A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) , 2008 .

[23]  C. Marosi,et al.  Tegwondo: Development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent brain tumors , 2008 .

[24]  W. Mason,et al.  Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study , 2008 .

[25]  W. Mason,et al.  The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma , 2008 .

[26]  P. Wen,et al.  Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma , 2008 .

[27]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[28]  Yiting Cao,et al.  Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Chauffert,et al.  [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. , 2008, Revue neurologique.

[30]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[31]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[32]  P. Wen,et al.  Inhibition of angiogenesis and invasion in malignant gliomas , 2007, Expert review of anticancer therapy.

[33]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Wei Chen,et al.  Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Chung,et al.  Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis , 2007, Clinical Cancer Research.

[36]  R. Gilbertson,et al.  Making a tumour's bed: glioblastoma stem cells and the vascular niche , 2007, Nature Reviews Cancer.

[37]  Christopher G Willett,et al.  Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Kenneth P. Roos,et al.  Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.

[39]  T. Mikkelsen,et al.  Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway , 2007, Oncogene.

[40]  Tristan Barrett,et al.  MRI of tumor angiogenesis , 2007, Journal of magnetic resonance imaging : JMRI.

[41]  R. Kerbel,et al.  Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. , 2007, Cancer research.

[42]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[43]  Tracy T Batchelor,et al.  Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. , 2007, Neuro-oncology.

[44]  R. Stupp,et al.  Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM) , 2007 .

[45]  M. Bent,et al.  The incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemo-radiation with temozolomide , 2007 .

[46]  T. Mikkelsen,et al.  Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009 , 2007 .

[47]  Tracy T Batchelor,et al.  VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. , 2007, Trends in molecular medicine.

[48]  M. Sekine,et al.  Vascular Endothelial Growth Factor Mediates Intracrine Survival in Human Breast Carcinoma Cells through Internally Expressed VEGFR1/FLT1 , 2007, PLoS medicine.

[49]  Gavin Thurston,et al.  The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth , 2007, Nature Reviews Cancer.

[50]  S. Horvath,et al.  Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 , 2007, Clinical Cancer Research.

[51]  T. Mikkelsen,et al.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  D. Hicklin,et al.  Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. , 2007, Cancer research.

[53]  W. Löscher,et al.  The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses , 2007, Clinical Cancer Research.

[54]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[55]  T. Gridley.  Vascular Biology: Vessel guidance , 2007, Nature.

[56]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[57]  V. Levin,et al.  Effect of bevacizumab on radiation necrosis of the brain. , 2007, International journal of radiation oncology, biology, physics.

[58]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[59]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[60]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[61]  James M Provenzale,et al.  Imaging of angiogenesis: clinical techniques and novel imaging methods. , 2007, AJR. American journal of roentgenology.

[62]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[63]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[64]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[65]  Napoleone Ferrara,et al.  Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective , 2006, Clinical Cancer Research.

[66]  J. Tonn,et al.  Expression of VEGFR3 in glioma endothelium correlates with tumor grade , 2007, Journal of Neuro-Oncology.

[67]  Andrew E. Sloan,et al.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma , 2007, Journal of Neuro-Oncology.

[68]  R. McLendon,et al.  Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas , 2007, Journal of Neuro-Oncology.

[69]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[70]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[71]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[72]  Robert S. Kerbel,et al.  The multifaceted circulating endothelial cell in cancer: towards marker and target identification , 2006, Nature Reviews Cancer.

[73]  I. Jonassen,et al.  Angiogenesis-independent tumor growth mediated by stem-like cancer cells , 2006, Proceedings of the National Academy of Sciences.

[74]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[75]  D. Scadden,et al.  Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. , 2006, Cancer research.

[76]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[77]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[78]  N. Hylton.  Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  N. Normanno,et al.  Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. , 2006, The oncologist.

[80]  Hyun Seok Song,et al.  Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. , 2006, Oncology reports.

[81]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[82]  P. Wen,et al.  Medical management of patients with brain tumors , 2006, Journal of Neuro-Oncology.

[83]  R. Kerbel.  Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? , 2006, Science.

[84]  S. Ylä-Herttuala,et al.  Biology of vascular endothelial growth factors , 2006, FEBS letters.

[85]  T. Cloughesy,et al.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006, Neurology.

[86]  R. Jain,et al.  Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. , 2006, Blood.

[87]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[88]  Lena Claesson-Welsh,et al.  Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.

[89]  W. Koch,et al.  Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[90]  A. Harris,et al.  Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. , 2006, Blood.

[91]  David N Louis,et al.  Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.

[92]  I. Weissman,et al.  Incorporation of Bone Marrow-derived Flk-1-expressing CD34+ Cells in the Endothelium of Tumor Vessels in the Mouse Brain , 2004, Neurosurgery.

[93]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[94]  K. Hess,et al.  Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme , 2006, Journal of Neuro-Oncology.

[95]  A. Kyritsis,et al.  Mechanisms of angiogenesis in gliomas , 2006, Journal of Neuro-Oncology.

[96]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  R. Kerbel,et al.  Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. , 2005, Blood.

[98]  K. Plate,et al.  The Role of Angiopoietins During Angiogenesis in Gliomas , 2005, Brain pathology.

[99]  R. Kerbel.  Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. , 2005, Cancer cell.

[100]  Dong-yan Wang,et al.  The Role of the Extracellular Matrix in Angiogenesis in Malignant Glioma Tumors , 2005, Brain pathology.

[101]  C. Gondi,et al.  Proteases and Glioma Angiogenesis , 2005, Brain pathology.

[102]  D. Zagzag,et al.  Angiogenesis in Gliomas: Biology and Molecular Pathophysiology , 2005, Brain pathology.

[103]  J. K. Smith,et al.  Vessel tortuosity and brain tumor malignancy: a blinded study. , 2005, Academic radiology.

[104]  D. Zagzag,et al.  Angiogenesis in Gliomas: Imaging and Experimental Therapeutics , 2005, Brain pathology.

[105]  G. Dresemann.  Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[106]  R. Benedito,et al.  Expression of Dll4 during mouse embryogenesis suggests multiple developmental roles. , 2005, Gene expression patterns : GEP.

[107]  Eric Masson,et al.  Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  Daniel J Brat,et al.  Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. , 2005, Neuro-oncology.

[109]  C. Gladson,et al.  Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. , 2005, Neuro-oncology.

[110]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[111]  A. Friedman,et al.  Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma , 2005, Cancer.

[112]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[113]  J. Dichgans,et al.  UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma , 2005, Journal of Neuro-Oncology.

[114]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[115]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[116]  Susan M. Chang,et al.  Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. , 2004, International journal of radiation oncology, biology, physics.

[117]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[118]  J. Provenzale,et al.  A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  J. Provenzale,et al.  A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[121]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[122]  S. Kollias,et al.  Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme , 2004, Journal of Neuro-Oncology.

[123]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[124]  N. Pavlakis,et al.  Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme , 2001, Journal of Neuro-Oncology.

[125]  A. Scott,et al.  Abstracts from the Ninth Annual Meeting of the Society for Neuro-Oncology , 2004 .

[126]  M. Gilbert,et al.  Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. , 2004, Neuro-oncology.

[127]  M. Westphal,et al.  Angiogenesis-related growth factors in brain tumors. , 2004, Cancer treatment and research.

[128]  M. Gore,et al.  Thalidomide as an Anti-angiogenic Agent in Relapsed Gliomas , 2004, Journal of Neuro-Oncology.

[129]  R. Grobholz,et al.  Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme , 2004, Journal of Cancer Research and Clinical Oncology.

[130]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[131]  E. Maher,et al.  Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  D. Carbone,et al.  VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. , 2003, Blood.

[133]  J. Verweij,et al.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours , 2003 .

[134]  W. Cavenee,et al.  Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. , 2003, The American journal of pathology.

[135]  J. Redondo,et al.  Cyclooxygenase-2: a therapeutic target in angiogenesis. , 2003, Trends in molecular medicine.

[136]  M. Makuuchi,et al.  G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. , 2002, Biochemical and biophysical research communications.

[137]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[138]  N. Ferrara,et al.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism , 2002, Nature.

[139]  D. Fabbro,et al.  Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth , 2001, British Journal of Cancer.

[140]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[141]  P. Black,et al.  Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. , 2001, Cancer research.

[142]  R K Jain,et al.  Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. , 2001, Cancer research.

[143]  B. Scheithauer,et al.  A phase III study of radiation therapy plus carmustine with or without recombinant interferon‐α in the treatment of patients with newly diagnosed high‐grade glioma , 2001 .

[144]  L. Grochow,et al.  Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  B. Scheithauer,et al.  A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. , 2001, Cancer.

[146]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[147]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[148]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[149]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[150]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[151]  G. Semenza,et al.  Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .

[152]  R. Amirnovin,et al.  Vascular Apoptosis and Involution in Gliomas Precede Neovascularization: A Novel Concept for Glioma Growth and Angiogenesis , 2000, Laboratory Investigation.

[153]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[154]  S. Soker,et al.  Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[155]  P. Wen,et al.  Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  G. Semenza,et al.  Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. , 2000, Cancer.

[157]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[160]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[161]  R. Weichselbaum,et al.  Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. , 1999, Cancer research.

[162]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[163]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[164]  P. Wen,et al.  A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[165]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[166]  R K Jain,et al.  Tumor angiogenesis and interstitial hypertension. , 1996, Cancer research.

[167]  K. Plate,et al.  Vascular morphology and angiogenesis in glial tumors. , 1995, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[168]  R K Jain,et al.  Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. , 1994, Cancer research.

[169]  P. Workman,et al.  Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. , 1994, International journal of radiation oncology, biology, physics.

[170]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[171]  K. Plate,et al.  Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. , 1994, International journal of cancer.

[172]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[173]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[174]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[175]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.